trending Market Intelligence /marketintelligence/en/news-insights/trending/0_fob5z4o6imbmf00asqpq2 content esgSubNav
In This List

Cynata stem cell therapy gets US orphan drug status

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Cynata stem cell therapy gets US orphan drug status

The U.S. Food and Drug Administration granted orphan drug status to Cynata Therapeutics Ltd.'s stem cell therapy CYP-001.

The drug is meant to treat the acute graft versus host disease, which occurs after transplant procedures when immune cells from transplanted tissue attack the recipient. The disease has a high mortality rate.

The orphan drug status will help expedite development of CYP-001 and entitles Cynata to seven years of exclusive market rights and tax credits once the treatment is commercialized.

CYP-001 is being studied in an early stage trial.